Johnson Todd D, Braden Rebecca L, Christman Karen L
Department of Bioengineering, University of California San Diego, Sanford Consortium for Regenerative Medicine, 2880 Torrey Pines Scenic Dr., La Jolla, CA, 92037, USA.
Methods Mol Biol. 2014;1181:109-20. doi: 10.1007/978-1-4939-1047-2_10.
Injectable biomaterials have been developed as potential minimally invasive therapies for treating myocardial infarction (MI) and heart failure. Christman et al. first showed that the injection of a biomaterial alone into rat myocardium can improve cardiac function after MI (Christman et al. Tissue Eng 10:403-409, 2004). More recently, hydrogel forms of decellularized extracellular matrix (ECM) materials have shown substantial promise. Here we present the methods for fabricating an injectable cardiac specific ECM biomaterial shown to already have positive outcomes in small and large animal models for cardiac repair (Singelyn et al. Biomaterials 30:5409-5416, 2009; Singelyn et al. J Am Coll Cardiol 59:751-763, 2012; Seif-Naraghi et al. Sci Transl Med 5:173ra25, 2013). Also covered are the methods for the injection of a biomaterial into rat myocardium using a surgical approach through the diaphragm. Although the methods shown here are for injection of an acellular biomaterial, cells or other therapeutics could also be added to the injection for testing other regenerative medicine strategies.
可注射生物材料已被开发为治疗心肌梗死(MI)和心力衰竭的潜在微创疗法。克里斯曼等人首次表明,将生物材料单独注射到大鼠心肌中可改善心肌梗死后的心脏功能(克里斯曼等人,《组织工程》10:403 - 409,2004年)。最近,脱细胞细胞外基质(ECM)材料的水凝胶形式已显示出巨大的前景。在此,我们介绍了一种可注射的心脏特异性ECM生物材料的制备方法,该材料已在小型和大型动物心脏修复模型中显示出积极的效果(辛格林等人,《生物材料》30:5409 - 5416,2009年;辛格林等人,《美国心脏病学会杂志》59:751 - 763,2012年;赛义夫 - 纳拉吉等人,《科学转化医学》5:173ra25,2013年)。还涵盖了通过膈肌采用手术方法将生物材料注射到大鼠心肌中的方法。尽管这里展示的方法是用于注射无细胞生物材料,但也可以将细胞或其他治疗剂添加到注射物中,以测试其他再生医学策略。